无容量
易普利姆玛
医学
肾细胞癌
内科学
肿瘤科
癌症
免疫疗法
作者
Kousuke Ueda,Naoki Ito,Yuya Sakai,Satoshi Ohnishi,Taishi Hirano,Hirofumi Kurose,Katsuaki Chikui,Keiichiro Uemura,Kiyoaki Nishihara,Makoto Nakiri,Shigetaka Suekane,Tsukasa Igawa
标识
DOI：10.21873/anticanres.17333
摘要
Nivolumab and ipilimumab (NIVO+IPI) is standard therapy for patients with intermediate and poor risk advanced renal cell carcinoma (RCC). However, the efficacy and safety of NIVO+IPI in elderly patients aged >75 years remains unclear. This study aimed to determine the efficacy and safety of first-line NIVO+IPI treatment in patients aged >75 years with advanced RCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI
薰硝壤
不配.
xjcy
嗯哼
抱住仙人球
pcr163
坚强的广山
pluto
Singularity
寻道图强
不懈奋进
8R60d8
罗_
张三坟
paparazzi221
shinysparrow
个性的紫菜
热心市民小红花
Frank
zyt
皖公网安备34019202002308
